Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation TCT 2015

Percutaneous Aortic Valve Repair Technologies 4: The V8 BAV Technology Description and Clinical Results

Presenter: Alain G. Cribier, Eberhard Grube, Wesley R. Pedersen

October 12, 2015

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

Reflections on Transcatheter Aortic Valve Therapies from BAV to TAVR: Greatest Disappointments, Surprises, and Achievements

Presenter: A. Pieter Kappetein, Martin B. Leon, Howard C. Herrmann, Alain G. Cribier

September 13, 2014

Presentation

Outcomes of TEVAR in Acute, Complicated Type B Aortic Dissection

Presenter: 222732|Joseph Bavaria

February 03, 2014

Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar

January 31, 2013

Presentation TVT 2012

Case Management Challenges: When Is BAV Appropriate?

Presenter: Augusto Pichard

June 04, 2012

Presentation TCT 2012

The Association Between Duration of Clopidogrel Therapy After Saphenous Vein Graft Intervention And Long-Term Death And Myocardial Infarction

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Vicken Aharonian, Prakash Mansukhani, Gregg W. Stone, Naing Moore, Ric Hyett, Richard Contreras, Somjot S. Brar

January 03, 2012

Presentation TCT 2012

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Presenter: Emmanouil S. Brilakis, Aristotelis C. Papayannis, Abdul-rahman R. Abdel-karim, Tesfaldet T. Michael, Arif Mahmood, Lorenza B. Makke, Michele Roesle, Donald Haagen, Bavana V. Rangan, Subhash Banerjee

January 03, 2012

Advertisement

Percutaneous Aortic Valve Repair Technologies 4: The V8 BAV Technology Description and Clinical Results

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Reflections on Transcatheter Aortic Valve Therapies from BAV to TAVR: Greatest Disappointments, Surprises, and Achievements

Outcomes of TEVAR in Acute, Complicated Type B Aortic Dissection

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Case Management Challenges: When Is BAV Appropriate?

The Association Between Duration of Clopidogrel Therapy After Saphenous Vein Graft Intervention And Long-Term Death And Myocardial Infarction

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content